Related Experiment Video
Updated: Mar 2, 2026

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
Published on: November 13, 2012
Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview
Sushmita Bhatia1, Neha Bhatia1, Suresh Thareja1
1Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda, Punjab 151401, India.
Inavolisib, a PI3Kα inhibitor, shows promise for PIK3CA-mutated breast cancer. This next-generation drug offers improved efficacy and tolerance, targeting key cancer pathways.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- The PI3K/AKT/mTOR pathway is crucial in breast cancer progression and therapeutic resistance.
- Selective PI3Kα inhibition is needed for improved tolerance and efficacy in HR+/HER2- breast cancer.
- PIK3CA mutations drive cancer growth and are a target for novel therapies.
Purpose of the Study:
- To provide a comprehensive review of inavolisib, a novel PI3Kα inhibitor.
- To discuss its preclinical efficacy, mechanism of action, and potential in combination therapies.
- To explore resistance mechanisms and future directions for inavolisib in personalized oncology.
Main Methods:
- Review of preclinical data on inavolisib's structure and pharmacokinetics.
- Analysis of in vivo antitumor activity and mechanism of action studies.
- Evaluation of combination strategies and emerging resistance patterns.
Main Results:
- Inavolisib demonstrates enhanced potency and selectivity for PI3Kα.
- It exhibits superior antitumor activity with reduced off-target effects compared to older inhibitors.
- Preclinical studies support its potential in combination therapies for endocrine resistance.
Conclusions:
- Inavolisib represents a next-generation therapy for PIK3CA-mutated breast cancer.
- Its selectivity for PI3Kα offers therapeutic advantages and potential for personalized oncology.
- Further research into combination strategies and resistance mitigation is warranted.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
PI3K/mTOR/AKT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...